Lipella Pharmaceuticals Inc. SEC filings LIPO
Lipella Pharmaceuticals Inc. has 225 filings in SEC EDGAR's recent list, going back to Dec 9, 2005. Its latest annual report, Form 10-K, was filed on Mar 28, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Nov 14, 2025, covering the quarter ended Sep 30, 2025. The most recent current report (Form 8-K) was filed on Jul 15, 2026 (bankruptcy). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy
|
Jul 15, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Bankruptcy
|
Mar 31, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 4, 2026 | Feb 3, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 21, 2025 | Oct 20, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2025 | Oct 3, 2025 |
| 25-NSE | Delisting notice | Oct 6, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 18, 2025 | Sep 18, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 25, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Jun 20, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Other events
|
Jun 16, 2025 | Jun 16, 2025 |
| PRE 14A | Preliminary proxy statement | Jun 10, 2025 | Jul 21, 2025 |
| 8-K |
Current report
Listing notice
|
May 16, 2025 | May 16, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 15, 2025 | May 15, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Other events
|
Apr 14, 2025 | Apr 14, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Apr 9, 2025 | Apr 9, 2025 |
| 8-K |
Current report
Material agreement
|
Apr 7, 2025 | Apr 7, 2025 |
| 424B5 | Prospectus supplement | Apr 4, 2025 | — |
| 424B3 | Prospectus | Apr 4, 2025 | — |
| EFFECT | Filing | Apr 3, 2025 | — |
| CORRESP | Letter to the SEC | Apr 1, 2025 | — |
| D | Filing | Apr 1, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2025 | — |
| S-3 | Shelf registration | Mar 28, 2025 | — |
| 10-K | Annual report | Mar 28, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 11, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 3, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Material agreement
|
Feb 24, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 11, 2025 | Feb 11, 2025 |
| 424B3 | Prospectus | Jan 16, 2025 | — |
| EFFECT | Filing | Jan 15, 2025 | — |
| CORRESP | Letter to the SEC | Jan 13, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 13, 2025 | — |
| 8-K |
Current report
Listing notice
|
Jan 13, 2025 | Jan 10, 2025 |
| D | Filing | Jan 7, 2025 | — |
| S-3 | Shelf registration | Jan 7, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 6, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Dec 30, 2024 | Dec 30, 2024 |
| 8-K |
Current report
Other events
|
Dec 27, 2024 | Dec 27, 2024 |
| DEFA14A | Additional proxy material | Dec 20, 2024 | — |
| 8-K |
Current report
Other events
|
Dec 20, 2024 | Dec 20, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 10, 2024 | Dec 5, 2024 |
| DEFA14A | Additional proxy material | Dec 6, 2024 | — |
| 8-K |
Current report
Other events
|
Dec 6, 2024 | Dec 6, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| DEF 14A | Proxy statement | Nov 12, 2024 | Dec 6, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Nov 7, 2024 | Nov 7, 2024 |
| PRE 14A | Preliminary proxy statement | Nov 1, 2024 | Dec 6, 2024 |
| 8-K |
Current report
Other events
|
Nov 1, 2024 | Nov 1, 2024 |
| 8-K |
Current report
Listing notice
|
Oct 18, 2024 | Oct 18, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Sep 11, 2024 | Sep 11, 2024 |
| 8-K |
Current report
Listing notice
|
Aug 23, 2024 | Aug 23, 2024 |
| D | Filing | Aug 15, 2024 | — |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| ARS | Annual report to shareholders | Aug 12, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Aug 12, 2024 | Sep 10, 2024 |
| 8-K |
Current report
Other events
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 1, 2024 | Aug 1, 2024 |
| 424B5 | Prospectus supplement | Aug 1, 2024 | — |
| PRE 14A | Preliminary proxy statement | Jul 30, 2024 | Jul 30, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Listing notice
|
Apr 19, 2024 | Apr 19, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 12, 2024 | Apr 12, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 15, 2024 | Mar 15, 2024 |
| S-8 | Employee stock plan registration | Mar 15, 2024 | — |
| 424B3 | Prospectus | Feb 27, 2024 | — |
| 10-K | Annual report | Feb 27, 2024 | Dec 31, 2023 |
| EFFECT | Filing | Feb 8, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2024 | — |
| S-3 | Shelf registration | Feb 1, 2024 | — |
| 8-K |
Current report
Other events
|
Dec 1, 2023 | Dec 1, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 28, 2023 | Nov 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Nov 22, 2023 | Nov 22, 2023 |
| 424B3 | Prospectus | Nov 14, 2023 | — |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 424B3 | Prospectus | Nov 9, 2023 | — |
| EFFECT | Filing | Nov 8, 2023 | — |
| D | Filing | Nov 7, 2023 | — |
| CORRESP | Letter to the SEC | Nov 6, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 6, 2023 | — |
| S-1 | Registration statement | Nov 1, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 26, 2023 | Oct 23, 2023 |
| DEFA14A | Additional proxy material | Oct 11, 2023 | — |
| DEF 14A | Proxy statement | Oct 10, 2023 | Nov 21, 2023 |
| D | Filing | Sep 12, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2023 | Sep 11, 2023 |
| 424B3 | Prospectus | Aug 14, 2023 | — |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Material agreement
|
Aug 2, 2023 | Aug 2, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2023 | Jun 23, 2023 |
| S-8 POS | Form s-8 | Jun 6, 2023 | — |
| S-8 | Employee stock plan registration | Jun 2, 2023 | — |
| 8-K |
Current report
Officer or director change
|
Jun 1, 2023 | Jun 1, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2023 | May 15, 2023 |
| 424B3 | Prospectus | May 12, 2023 | — |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Apr 3, 2023 | Apr 3, 2023 |
| 424B3 | Prospectus | Apr 3, 2023 | — |
| POS EX | Filing | Apr 3, 2023 | — |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K/A | Amended current report | Feb 2, 2023 | Jan 11, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 12, 2023 | Jan 11, 2023 |
| 424B4 | Prospectus | Dec 21, 2022 | — |
| 424B4 | Prospectus | Dec 21, 2022 | — |
| CERT | Filing | Dec 20, 2022 | — |
| EFFECT | Filing | Dec 19, 2022 | — |
| 8-A12B | Filing | Dec 19, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2022 | — |
| CORRESP | Letter to the SEC | Dec 15, 2022 | — |
| S-1/A | Amended registration statement | Dec 15, 2022 | — |
| CORRESP | Letter to the SEC | Dec 13, 2022 | — |
| S-1/A | Amended registration statement | Dec 13, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2022 | — |
| CORRESP | Letter to the SEC | Dec 8, 2022 | — |
| S-1/A | Amended registration statement | Dec 8, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2022 | — |
| CORRESP | Letter to the SEC | Nov 28, 2022 | — |
| S-1/A | Amended registration statement | Nov 28, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2022 | — |
| CORRESP | Letter to the SEC | Oct 31, 2022 | — |
| S-1/A | Amended registration statement | Oct 24, 2022 | — |
| CORRESP | Letter to the SEC | Oct 21, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2022 | — |
| CORRESP | Letter to the SEC | Jul 29, 2022 | — |
| S-1 | Registration statement | Jul 29, 2022 | — |
| UPLOAD | Letter from the SEC | May 2, 2022 | — |
| DRSLTR | Filing | Apr 20, 2022 | — |
| DRSLTR | Filing | Apr 20, 2022 | — |
| DRS/A | Filing | Apr 20, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2022 | — |
| DRSLTR | Filing | Feb 14, 2022 | — |
| DRS | Filing | Feb 14, 2022 | — |
| D/A | Filing | May 17, 2021 | — |
| D/A | Filing | Apr 12, 2021 | — |
| D | Filing | Nov 4, 2020 | — |
| D/A | Filing | Jan 27, 2011 | — |
| D/A | Filing | Jan 29, 2010 | — |
| D/A | Filing | Sep 29, 2009 | — |
| REGDEX/A | Auto-generated paper document | Sep 30, 2008 | — |
| REGDEX | Auto-generated paper document | Aug 8, 2008 | — |
| REGDEX | Auto-generated paper document | Jun 27, 2008 | — |
| REGDEX | Auto-generated paper document | May 8, 2008 | — |
| REGDEX/A | Auto-generated paper document | Feb 14, 2008 | — |
| REGDEX | Auto-generated paper document | Dec 19, 2006 | — |
| REGDEX | Auto-generated paper document | Dec 9, 2005 | — |
Showing 151 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIPO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pittsburgh, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1347242
- Former names
- LIPELLA PHARMACEUTICALS INC (until Sep 11, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.